Carfilzomib

Generic Name
Carfilzomib
Brand Names
Kyprolis
Drug Type
Small Molecule
Chemical Formula
C40H57N5O7
CAS Number
868540-17-4
Unique Ingredient Identifier
72X6E3J5AR
Background

Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.

Indication

Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...

Associated Conditions
Relapsed/Refractory Multiple Myeloma (RRMM)
Associated Therapies
-
Clinical Trials
Related News

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

First Posted Date
2021-09-20
Last Posted Date
2024-12-10
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
166
Registration Number
NCT05050097
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

Indiana University, Indianapolis, Indiana, United States

🇺🇸

Tennessee Oncology, Nashville, Tennessee, United States

and more 28 locations

A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma

First Posted Date
2021-07-22
Last Posted Date
2024-12-13
Lead Sponsor
BeiGene
Target Recruit Count
167
Registration Number
NCT04973605
Locations
🇺🇸

City of Hope At Irvine Lennar, Irvine, California, United States

🇺🇸

Southern Illinois University School of Medicine, Springfield, Illinois, United States

🇺🇸

University of California At San Francisco, San Francisco, California, United States

and more 85 locations

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Phase 2
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Drug: Dexamethasone
Drug: Carfilzomib
Biological: Daratumumab
First Posted Date
2021-06-21
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
11
Registration Number
NCT04933539
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

First Posted Date
2021-06-14
Last Posted Date
2024-08-13
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
18
Registration Number
NCT04925193
Locations
🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

First Posted Date
2021-05-20
Last Posted Date
2023-03-06
Lead Sponsor
AbbVie
Target Recruit Count
8
Registration Number
NCT04895410
Locations
🇺🇸

Moffitt Cancer Center /ID# 229939, Tampa, Florida, United States

🇺🇸

Norton Cancer Institute - St Matthews /ID# 229319, Louisville, Kentucky, United States

🇺🇸

University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 229309, Ann Arbor, Michigan, United States

and more 29 locations

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

First Posted Date
2021-05-19
Last Posted Date
2024-11-01
Lead Sponsor
Gilead Sciences
Target Recruit Count
35
Registration Number
NCT04892446
Locations
🇺🇸

US Oncology, Inc., IRB, Fairfax, Virginia, United States

🇺🇸

US San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

Stanford Cancer Institute, Palo Alto, California, United States

and more 19 locations

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

First Posted Date
2021-05-12
Last Posted Date
2024-07-03
Lead Sponsor
University of Washington
Target Recruit Count
37
Registration Number
NCT04883242
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

First Posted Date
2021-04-20
Last Posted Date
2024-12-05
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
5
Registration Number
NCT04850599
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

First Posted Date
2021-02-21
Last Posted Date
2024-01-17
Lead Sponsor
Mayo Clinic
Target Recruit Count
81
Registration Number
NCT04764942
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

First Posted Date
2021-02-16
Last Posted Date
2024-05-28
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
52
Registration Number
NCT04756401
Locations
🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

State University of New York Upstate Medical University, Syracuse, New York, United States

🇺🇸

UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy